Kronos Bio, Inc. (NASDAQ:KRON - Get Rating) - Stock analysts at HC Wainwright issued their FY2023 earnings per share (EPS) estimates for Kronos Bio in a research note issued to investors on Friday, November 18th. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($2.16) for the year. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Kronos Bio's current full-year earnings is ($2.49) per share.
Several other equities research analysts also recently weighed in on the company. The Goldman Sachs Group decreased their price objective on Kronos Bio from $25.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, November 10th. Berenberg Bank initiated coverage on Kronos Bio in a report on Wednesday, September 14th. They set a "buy" rating and a $12.00 price target for the company. Finally, Piper Sandler decreased their price target on Kronos Bio from $13.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday, November 9th.
Kronos Bio Stock Down 1.8 %
Shares of KRON opened at $2.13 on Monday. The company has a market capitalization of $121.19 million, a price-to-earnings ratio of -0.72 and a beta of 1.29. Kronos Bio has a 52-week low of $2.11 and a 52-week high of $15.80. The stock has a 50 day moving average price of $3.16 and a 200 day moving average price of $3.84.
Institutional Investors Weigh In On Kronos Bio
Hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC purchased a new position in Kronos Bio in the first quarter worth $25,000. Algert Global LLC purchased a new position in Kronos Bio in the third quarter worth $34,000. Amalgamated Bank purchased a new position in Kronos Bio in the first quarter worth $35,000. Point72 Asset Management L.P. purchased a new position in Kronos Bio in the second quarter worth $41,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Kronos Bio in the second quarter worth $46,000. 62.62% of the stock is owned by institutional investors and hedge funds.
Kronos Bio Company Profile
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Kronos Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kronos Bio wasn't on the list.
While Kronos Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here